<DOC>
	<DOCNO>NCT02934139</DOCNO>
	<brief_summary>The present study design ass safety tolerability escalating , multiple ascend dos Cavosonstat ( N91115 ) healthy subject .</brief_summary>
	<brief_title>MAD Study Evaluating Safety , Tolerability , Pharmacokinetics Cavosonstat ( N91115 ) Healthy Subjects ( SNO-9 )</brief_title>
	<detailed_description>This study ass safety tolerability escalating , multiple ascend dos Cavosonstat ( N91115 ) healthy subject . Approximately 5 ascend cohort plan approximately 8 subject per cohort ( 6 active , 2 placebo ) . Each subject undergo screening ( Day -28 Day -2 ) , eligible , return unit Day -1 eligibility reconfirm . Eligible subject randomize 3:1 ratio receive investigational medicinal product ( IMP ) N91115 ( daily [ QD ] every 12 hour [ Q12H ] ) match placebo ( QD Q12H ) 7 day follow safety house clinical research unit ( CRU ) discharge Day 8 . Pharmacokinetics follow Study Day 1 morning Study Day 8 . The subject discharge CRU complete post treatment withdrawal phase , include follow-up phone call Day 15 .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Written inform consent 2 . Healthy , determine screen medical evaluation ( include limit medical history , physical examination , clinical laboratory evaluation ) 3 . Male female , 18 55 year age , inclusive screen 4 . Caucasian ( reported patient ) 5 . The following applies female subject : 1 . Negative serum pregnancy test ( woman childbearing potential ) screen negative urine pregnancy Day 1 2 . Willing use least 1 highly effective method birth control ( exclude hormonal contraceptive ) sign consent , include abstinence must use time consent 30 day complete doubleblind study drug 6 . The following applies male subject : 1 . Agrees use condom abstinence , agree refrain sperm donation date inform consent sign 30 day complete doubleblind study drug 2 . Has documentation azoospermia vasectomy 7 . Nonsmoker ( nicotine user ) determine history ( nicotine use past 6 month ) negative cotinine test screen Day 1 8 . Body mass index 18 32 kg/m2 inclusive screening , weigh least 50 kg screen 9 . No clinically significant vital sign finding include clinically significant abnormal finding relate systolic diastolic BP screen prior dose Day 1 , per investigator 's judgment . 10 . No clinically significant abnormal finding 12lead ECG , per investigator 's judgment , screen prior dose Day 1 11 . No clinically significant abnormality hematology , clinical chemistry , urinalysis result would interfere study assessment screen 1 . History illness condition opinion investigator could confound result study pose additional risk administer IMP , clinically significant history evidence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , immunological , psychiatric disorder ( ) determine investigator designee 2 . Concurrent disease condition , , opinion investigator , would make subject unsuitable participation clinical study 3 . Any following finding 12lead ECG do screening : 1 . HR &lt; 45 bpm &gt; 95 bpm 2 . QTcF &gt; 450 msec male &gt; 470 msec female 3 . PR &gt; 220 msec 4 . QRS duration &gt; 110 msec 5 . ST segment abnormal 6 . Twave change 7 . QRS , ST , Twave finding make technically difficult determine QT intervals 4 . Any follow 24hour ambulatory ECG ( Holter ) monitor screening : a. Supraventricular ectopy i. Singlets : &gt; 200 / 24 hour ii . Couplets : &gt; 20 / hour iii . Runs : &gt; 10 beat b. Ventricular ectopy i. Unifocal singlet : &gt; 100 / 24 hour ii . Unifocal couplet : &gt; 20 / hour iii . Complex multifocal singlet : &gt; 50 / 24 hour iv . Complex multifocal couplet : &gt; 10 / 24 hour v. Any Run ( ventricular tachycardia ) c. Heart rate . &lt; 40 bpm 1 minute awake ii . &lt; 35 bpm 3 minute asleep iii . &gt; 120 bpm 3 minute ( exercise ) iv . Pauses &gt; 2000 msec d. 2nd 3rd degree AV block e. Intraventricular conduction delay ( IVCD ) QRS duration &gt; 120 msec right bundle branch block ( RBBB ) leave buddle branch block ( LBBB ) rare RBBB f. Atrial flutter atrial fibrillation regardless rate 5 . Disorder would interfere absorption , distribution , metabolism , excretion drug determine investigator 6 . History alcohol abuse drug abuse ( include cannabis , cocaine , opioids ) year prior screen 7 . Positive alcohol test screen Day 1 . 8 . Positive drug test ( include limit cocaine , amphetamine , barbiturate , opiate , benzodiazepine ) screen Day 1. . A positive drug test cannabinoids screen allow subject agrees abstain use form cannabinoids screen throughout study negative test Day 1 9 . Positive screen test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . 10 . Unwilling limit consumption coffee caffeinecontaining food beverage Day 1 discharge Day 8 . 11 . Unwilling avoid use alcohol alcoholcontaining food , medication , beverage Day 1 discharge Day 8 . 12 . Subject donate blood ( &gt; 500 mL ) blood product within 56 day prior Day 1 . 13 . Use vitamin Day 7 endofstudy follow call , use overthecounter ( OTC ) medication , prescription medication , herbal remedy Day 14 endofstudy followup call . By exception , acetaminophen â‰¤ 1000 mg/day permit except within 48 hour prior Day 1 . Hormone replacement therapy ( HRT ) hormonal contraception allow throughout study . The Medical Monitor Principal Investigator may allow certain OTC medication exception likely affect study conduct output . 14 . Use investigational drug within 30 day prior Day 1 dosing . 15 . Unwilling abstain vigorous exercise Day 1 discharge Day 8 . 16 . Problems understand protocol requirement , instruction study relate restriction , nature , scope , possible consequence clinical study . 17 . Unlikely comply protocol requirement , instruction , study related restriction ; e.g. , uncooperative attitude , unavailable followup call , and/or improbability complete clinical study . 18 . History bleed disorder ( i.e. , severe hemorrhage , melena , rectal bleeding , nosebleed , bruising , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>N91115</keyword>
	<keyword>Cavosonstat</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>